Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC
Thomas Longval,Anne-Claire Leprêtre,Aurélie Ravinet,Amandine Fayard,Edouard Forcade,Tereza Coman,Rabah Redjoul,Ana Berceanu,Nimrod Buchbinder,Guillaume Berlie,Maria Mappoura,Federica Giannotti,Florian Chevillon,Marie Robin,Régis Peffault de Latour,Flore Sicre de Fontbrune,the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC),Members,Non-members
DOI: https://doi.org/10.1038/s41409-024-02202-9
2024-03-12
Bone Marrow Transplantation
Abstract:Pure Red Cell Aplasia (PRCA) after ABO-mismatched Hematopoietic Stem Cell Transplant (HSCT) remains a challenge for physicians. It occurs in 7 to 10% [1,2,3] of major or bi-directional ABO-incompatible HSCT. Although it does not affect overall survival [3, 4], post-transplant PRCA significantly impairs patients' quality of life due to fatigue, iron-overload and increased risk of transfusion complications. Half of the patients resolve PRCA within six months after transplant but others experience prolonged PRCA with no decrease of their isohemagglutinin titers. There is an unmet medical need for these patients', as no treatment has yet demonstrated efficacy [3, 4]. Moreover, the scarcity of PRCA cases results in a lack of prospective data. Among other strategies, plasma cell targeted therapies seem the most promising approach given that the physiology of prolonged PRCA is presumably a reflection of residual host plasma cell clones [5] producing isohemagglutinins. Daratumumab is a humanized monoclonal antibody targeting CD38, commonly used to treat plasma cell disorders. Since the first report in 2018 by Chapuy et al. [6] of PRCA recovery after 6 weekly Daratumumab infusions, ten other successful cases have been reported [7,8,9,10,11,12,13,14] with variations in the management of Daratumumab. In their letter, Martino et al. [14] provide a comprehensive review of published case reports. Here, we further contribute to this field by presenting a systematic report of PRCA patients treated in centers affiliated with the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
oncology,immunology,hematology,transplantation